Compare Ascendis Pharma A/S (ASND) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs UnitedHealth Group Inc — how do they compare? Ascendis Pharma A/S trades at $257.5 (market cap $16.67B), while UnitedHealth Group Inc trades at $405.35 (market cap $361.00B). The key difference: UnitedHealth Group Inc is far larger — about 21.7× Ascendis Pharma A/S's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UNH | |
|---|---|---|
Market Cap | $16.67B | $361.00B |
Sector | Health | Health |
52-Week High | $277.18 | $436.35 |
52-Week Low | $189.74 | $259.02 |
Enterprise Value | $17.04B | $402.86B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.
UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
